May 29 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH® PRESENTS CLINICAL PROOF-OF-CONCEPT DATA IN MULTIPLE MYELOMA AT THE ASCO VIRTUAL ANNUAL MEETING
* ONCOLYTICS BIOTECH INC - COMBINATION THERAPY WITH PELAREOREP ACTIVATES A PROFOUND INFLAMMATORY RESPONSE
* ONCOLYTICS BIOTECH - 50% OVERALL RESPONSE RATE, 83% CLINICAL BENEFIT RATE IN PATIENTS WHO FAILED CARFILZOMIB